SCHEMBL7776599

SCHEMBL7776599

Cc1ccc(S(=O)(=O)NCCOCCO)cc1

nearest known ligand 0.84

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 13/20 0.84
LMNA P02545 2/20 0.61
HPGD P15428 2/20 0.61
HTT P42858 1/20 0.61
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
CA12 O43570 1/20 0.55
CA2 P00918 1/20 0.55
CA9 Q16790 1/20 0.55
ALOX15 P16050 1/20 0.54
MAPT P10636 2/20 0.51
KDM4E B2RXH2 1/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
TSHR P16473 1/20 0.49
USP2 O75604 1/20 0.49
GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26219802 0.98 ALDH1A1 (0.82) ALDH1A1LMNAHPGDHTTMEN1
SCHEMBL18894208 0.92 ALDH1A1 (1.00) ALDH1A1LMNAHPGDHTTMEN1
SCHEMBL9066249 0.90 ALDH1A1 (0.96) ALDH1A1LMNAHPGDHTTMEN1
SCHEMBL8048430 0.90 ALDH1A1 (0.96) ALDH1A1LMNAHPGDHTTMEN1
SCHEMBL12169334 0.86 ALDH1A1 (0.87) ALDH1A1LMNAHPGDHTTMEN1
SCHEMBL23476689 0.84 ALDH1A1 (0.59) ALDH1A1LMNAHPGDCA2MAPT
SCHEMBL5893917 0.84 ALDH1A1 (0.59) ALDH1A1LMNAHPGDCA12CA2
SCHEMBL29316529 0.84 ALDH1A1 (0.84) ALDH1A1LMNAHPGDHTTMEN1
SCHEMBL439077 0.84 ALDH1A1 (0.84) ALDH1A1LMNAHPGDHTTMEN1
SCHEMBL16503455 0.84 ALDH1A1 (0.84) ALDH1A1LMNAHPGDHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230321016-A1 COMBINATION THERAPY FOR TREATING CANCER GONGWIN BIOPHARM CO., LTD (TW) 2023-10-12 US disclosed
US-11752118-B2 Method for treating melanoma GONGWIN BIOPHARM CO., LTD (TW) 2023-09-12 US disclosed
US-11752160-B2 Method for reducing fat by administering benzenesulfonamide compositions GONGWIN BIOPHARM CO., LTD (TW) 2023-09-12 US disclosed
US-20220168248-A1 METHOD FOR TREATING MELANOMA GONGWIN BIOPHARM CO., LTD (TW) 2022-06-02 US disclosed
US-20200338028-A1 BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR MODULATING LIPID RAFT GONGWIN BIOPHARM CO., LTD. (TW) 2020-10-29 US disclosed
US-10548862-B2 Topical formulation and method for preventing or treating acne Wu, Lester J. (US) 2020-02-04 US disclosed
US-20190321313-A1 BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR TREATING CANCER Gongwin Biopharm Holdings Co., Ltd. 2019-10-24 US disclosed
US-20190322650-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-10-24 US disclosed
US-20190201356-A1 TOPICAL FORMULATION AND METHOD FOR PREVENTING OR TREATING ACNE GONGWIN BIOPHARM CO., LTD. (TW) 2019-07-04 US disclosed
US-10338277-B2 Polarizing plate protective film, polarizing plate, and display FUJIFILM CORPORATION (JP) 2019-07-02 US disclosed
US-20140206689-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-07-24 US disclosed
US-8722704-B2 Modulators of ATP-binding cassette-transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-05-13 US disclosed
US-20130296364-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-11-07 US disclosed
US-20130245010-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2013-09-19 US disclosed
US-20130245010-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2013-09-19 US disclosed
US-8461156-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-11 US disclosed
US-8324207-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-04 US disclosed
EP-0477912-B1 Novel N-acyldipeptides, and pharmaceutical compositions containing the same UNIV LJUBLJANI (SI) 2001-08-29 EP disclosed
US-5514654-A ANTITUMOR AGENTS AND IMMUNOMODULATORS UNIV LJUBLJANI (SI) 1996-05-07 US disclosed
EP-0477912-A2 Novel N-acyldipeptides, processes for the preparation thereof and pharmaceutical compositions containing the same UNIVERZA EDVARDA KARDELJA V LJUBLJANI, VDO FAKULTETA ZA NARAVOSLOVJE IN TEHNOLOGIJO, N.SOL.O., LUBLJANA (YU) 1992-04-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190321313-A1 BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR TREATING CANCER ARSA, ABCB1, ABCG2 ALDH1A1 689/4885LMNA 3088/4885HPGD 1032/4885
US-20130245010-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 ALDH1A1 1991/4885LMNA 3485/4885HPGD 1969/4885
US-10548862-B2 Topical formulation and method for preventing or treating acne CUTA, STS, ALAD ALDH1A1 669/4885LMNA 3159/4885HPGD 410/4885
US-20190322650-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 ALDH1A1 1786/4885LMNA 3535/4885HPGD 1792/4885
US-20130296364-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS CFTR, ABCB1, ABCC2 ALDH1A1 1985/4885LMNA 3826/4885HPGD 1862/4885
US-11752160-B2 Method for reducing fat by administering benzenesulfonamide compositions LIPE, FABP4, LIPA ALDH1A1 728/4885LMNA 920/4885HPGD 730/4885
US-20220168248-A1 METHOD FOR TREATING MELANOMA TYR, MITF, BRAF ALDH1A1 528/4885LMNA 2154/4885HPGD 784/4885
US-20230321016-A1 COMBINATION THERAPY FOR TREATING CANCER TP53, MCL1, TOP2B ALDH1A1 381/4885LMNA 2924/4885HPGD 687/4885
US-11752118-B2 Method for treating melanoma TYR, MITF, BRAF ALDH1A1 528/4885LMNA 2154/4885HPGD 784/4885
US-20140206689-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 ALDH1A1 1786/4885LMNA 3535/4885HPGD 1792/4885
US-20200338028-A1 BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR MODULATING LIPID RAFT ABCB4, SPTSSB, SMPD2 ALDH1A1 1604/4885LMNA 772/4885HPGD 1633/4885
US-20190201356-A1 TOPICAL FORMULATION AND METHOD FOR PREVENTING OR TREATING ACNE CUTA, STS, ALAD ALDH1A1 669/4885LMNA 3159/4885HPGD 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.